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P-selectinAbstract Background: Hypercoagulability in thalassemia especially in thalassemia major has
emerged as a complication of the disease. There is evidence of increased platelet aggregation and
increased proportion of platelets expressing P-selectin in thalassemia. P-selectin is a cell adhesion
molecule which plays a key role in hemostasis and thrombosis, mediating platelet rolling and gen-
erating procoagulant molecules. Substance P is one of the tachykinins which constitute a family of
neuropeptides. It now appears that platelets contain substance P which is released upon stimulation
leading to faster and more extensive aggregation.
Objective: To detect the possible role of substance P and soluble P-selectin (sP-selectin) as bio-
markers of hypercoagulability in patients with beta-thalassemia major.
Subjects and methods: Venous blood samples were collected from ten normal control subjects and
thirty patients with beta-thalassemia major (divided into two groups, splenectomized and unsple-
nectomized). To all studied individuals, plasma substance P and sP-selectin were assayed by an
enzyme linked Immunosorbent assay (ELISA).
108 S.A. Ebeid et al.Results: Higher levels of plasma substance P and sP-selectin were observed in thalassemic patients
versus the controls. Both substance P and sP-selectin were signiﬁcantly higher in the splenectomized
group of patients.
Conclusions: Substance P and sP-selectin might have a role in platelet activation and subsequent
hypercoagulability in thalassemic patients.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
beta-thalassemia is an inherited autosomal recessive hemato-
logic disorder that causes hemolytic anemia because of the de-
creased or absent synthesis of the beta-globin chain.1 In Egypt,
it was estimated that 1000/1.5 million per year live births will
suffer from thalassemia. beta-thalassemia is the most common
type with a carrier rate ranging from 5.3% toP9% and a gene
frequency of 0.03%.2
beta-thalassemia is clinically classiﬁed into: thalassemia
major, intermedia and minor depending on the demand
for blood transfusion and pathophysiology. The mainstay
of managing these patients relies on blood transfusion and
chelation. A state of hypercoagulability has been recognized
in beta-thalassemia but the mechanisms underlying it are
still unsettled.3
Platelet activation has been incriminated in starting the
hypercoagulable state. Enhanced thrombin generation acti-
vates the platelets, monocytes, granulocytes and endothelial
cells which further enhance the prothrombotic process. 4 There
is evidence of increased platelet aggregation and increased pro-
portion of platelets expressing P-selectin in thalassemia. P-
selectin (CD62P) is a member of the selectin family of cell
adhesion receptors, which mediate binding to speciﬁc carbohy-
drate ligands. 5 P-selectin is stored in a-granules of platelets
and Weibel–Palade bodies of endothelial cells. 6 Upon cellular
activation, P-selectin translocates with the granule to the cell
surface, where it mediates adhesion to leukocytes or
endothelium.7
Substance P is a member of the tachykinin family of pep-
tides and has clinically been considered a neuropeptide. Its
interaction with tachykinin receptors on vascular endothelial
or smooth muscle cells can cause vasodilation or contraction,
respectively.8 It now appears that platelets contain substance
P which is released upon stimulation leading to faster and
more extensive aggregation.9
The aim of the present work was to investigate the role of
plasma substance P and soluble P-selectin (sP-selectin) as
biomarkers of beta-thalassemia induced hypercoagulability.2. Subjects and methods
Thirty patients with beta-thalassemia major followed up at
the Hematology Department, Medical Research Institute
were enrolled. A written consent for participating in the
study was taken according to the declaration of Helsinki
and approved by the ethics committee of the Medical Re-
search Institute. Because splenectomy is a well known risk
factor for thrombosis in thalassemia patients,10 they were di-
vided into two groups:2.1. Group I
Fifteen unsplenectomized patients, their mean age was (22.37
± 8.96) years.
2.2. Group II
Fifteen splenectomized patients, their mean age was (20.28 ±
7.53) years.
Ten age and sex matched healthy individuals served as nor-
mal control group. Venous blood sample was withdrawn from
control subjects and from patients after an overnight fasting
and just prior to blood transfusion. To all studied individuals,
a full history taking and clinical examination were done. Lab-
oratory investigations included: complete blood picture,11 ser-
um ferritin and liver and kidney function tests. The plasma
levels of circulating substance P and sP-selectin were assayed
by ELISA (R&D Systems, USA).
All patients received blood transfusion at a rate of one unit
packed red blood cells every fortnight. They were chelated by
desferrioxamine and the oral chelator deferipone. Most of
them were infected with hepatitis C virus.
2.3. Statistical analyses
Statistical analyses were conducted using the statistical soft-
ware package of SPSS version 11.5 (SPSS Inc, Chicago,
USA). Differences between groups were assessed by the Mann
Whitney U test for nonparametric variables. Pearson’s correla-
tion coefﬁcients were calculated to evaluate the association be-
tween relevant parameters. Statistical signiﬁcance was set at
p< 0.05.
3. Results
As can been seen in (Table 1), there was no statistically signif-
icant difference in white blood cell count (WBC) among the
studied groups and controls (P= 0.97 and P= 0.46 respec-
tively). No statistically signiﬁcant difference was found in
hemoglobin concentration on comparing both groups. A sig-
niﬁcantly higher normoblast count (/100WBC) was found in
the splenectomized group compared to the unsplenectomized
group (P= 0.001). The mean platelet volume (MPV) did not
differ among the studied groups. The median value of platelet
count in the splenectomized group was signiﬁcantly higher
than that in control and unsplenectomized groups
(P= 0.001 and P= 0.000 respectively). Furthermore, sple-
nectomized group had a higher serum ferritin level compared
to the unsplenectomized group (P= 0.021). Also it was higher
in patient groups versus the controls (P= 0.000).
Table 1 Hematological results in all studied groups.
Patients with b thalassemia major
Control group (n= 10) Unsplenectomized group (n= 15) Splenectomized group (n= 15)
WBC (·109/L) Range 5–8 4.2–10 3.3–46.8
Median 6.5 6.0 7.6
P 0.97 0.46
0.49
Hb (g/dl) Range 11.6–14.9 6.4–10.5 7.1–10.9
Median 12.65 8.75 8.2
P 0.000* 0.000*
0.093
Normoblast count/100 WBC Range 0–0 0–80 0–460
Median 0 20 31
P 0.006* 0.001*
0.001§
Platelets (·109/L) Range 217–402 115–458 251–629
Median 253.5 232.5 378
P 0.413 0.001*
0.000§
MPV Range 8.6–10.9 7.9–10.7 8.1–10.3
Median 9.15 9.25 9.2
P 0.731 0.820
0.971
Ferritin (ng/ml) Range 41–90 804–11400 1070–8700
Median 58.5 1356.5 3200
P 0.000* 0.000*
0.021§
Signiﬁcance was considered at level of P 6 0.05.
* Signiﬁcantly different from control group.
§ Signiﬁcantly different from unsplenectomized group.
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thalassemic patients versus the controls (P= 0.000) especially
in the splenectomized group (P= 0.009) but no signiﬁcant
difference was found between both patient groups. Regarding
sP-selectin, it was signiﬁcantly higher in the patient groups
compared to the control (P= 0.037) and especially in the
splenectomized group compared to unsplenectomized group
and the controls (P= 0.016 and P= 0.003 respectively)
(Table 2).
A signiﬁcant positive correlation was found between sP-
selectin and plasma substance P (P= 0.000), WBCs count
(P= 0.025), normoblasts (P= 0.040) and MCV
(P= 0.022). Additionally, a borderline signiﬁcance was found
with serum ferritin (P= 0.053) while there was no signiﬁcant
correlation with platelet count (P= 0.584) or MPV
(P= 0.867) (Table 3).
With respect to substance P, a signiﬁcant negative correla-
tion was observed between plasma substance P and MPV
(P= 0.034). On the other hand, there was no signiﬁcant cor-
relation between plasma substance P and WBC count
(P= 0.073), normoblasts (P= 0.503), MCV (P= 0.083),
platelet count (P= 0.123) or serum ferritin (P= 0.257) in
all patients with b-thalassemia major (Table 3).
4. Discussion
A profound hemostatic derangement has been observed in
patients with thalassemia4, yet the mechanism underlyingthis hypercoagulable state is multifactorial.12–18 Platelet activa-
tion has been incriminated. It is caused by the scavenging of
endothelial-derived nitric oxide (NO) which causes vasocon-
striction and decreased blood ﬂow.19 Thrombocytosis and
spontaneous platelet activation and aggregation, especially
after splenectomy remains an attractive pathophysiologic is-
sue.20 This has been observed in the present study where
thrombocytosis was signiﬁcant in splenectomized patients
which by itself predisposes them to thrombosis.
In the present study, a signiﬁcant increase in sP-selectin
was observed in thalassemic patients especially in the
splenectomized group reﬂecting a state of endothelial
activation and damage which further enhances platelet
activation. This is in agreement with Kanawaki et al.21
and Krishman et al.22 In addition, Kato et al.18 showed in-
creased plasma levels of vascular cell adhesion molecules (sVC-
AMs), sE-selectin, sP-selectin in sickle cell patients compared
to healthy individuals. In addition, Hayashi et al.23 reported
that P-selectin plays a key role in immune system mediated
inﬂammation through promoting the adherence of leukocytes
to activated platelets and endothelium, leukocyte migration,
cytokine release and secretion of growth factors at the site of
injury. Furthermore, many authors highlighted the role of
sP-selectin in arterial thrombogenesis by forming large stable
platelet leukocyte aggregates.24,25 Our ﬁndings are also sup-
ported by Sullivan et al.26 and Smyth et al.27 who demon-
strated that venous thrombosis was decreased in P-selectin
deﬁcient mice.
Table 2 Plasma substance P and sP-selectin in all studied groups.
Control group
(n= 10)
Patients with b thalassemia
major (n= 30)
Patients with b
thalassemia major
Unsplenectomized
group (n= 15)
Splenectomized
group (n= 15)
Substance P
(pg/mL)
Range 28 – 192 40–7000 40–1820 144–
7000
Median 125 176 172 182
P 0.000* 0.061 0.009*
0.241
sP-selectin
(ng/mL)
Range 20–42 20–280 20–110 20–280
Median 30 40 32 50
P 0.037* 0.472 0.003*
0.016§
Signiﬁcance was considered at level of P 6 0.05.
* Signiﬁcantly different from the control group.
§ Signiﬁcantly different from the unsplenectomized group.
Table 3 Correlation between plasma substance P and sP-
selectin with laboratory parameters in all patients with b
thalassemia major.
Substance P (n= 30) sP-selectin (n= 30)
WBCs count r= 0.317 r= 0.391
P= 0.073 P= 0.025*
Normoblasts r= 0.121 r= 0.359
P= 0.503 P= 0.040*
MCV r= 0.307 r= 0.398
P= 0.083 P= 0.022*
Platelet count r= 0.274 r= 0.099
P= 0.123 P= 0.584
MPV r= - 0.369 r= 0.030
P= 0.034* P= 0.867
Serum ferritin r= 0.203 r= 0.340
P= 0.257 P= 0.053
Substance P – r= 0.607
P= 0.000*
r: Pearson coefﬁcient.
* Signiﬁcance was considered at level of P 6 0.05.
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tween sP-selectin, a marker of platelet activation, and normo-
blast count reﬂecting the relation between platelet activation
and the subsequent prothrombotic state and normoblasts. This
agrees with Garozzo and his colleagues17 who explained the
hypercoagulable status of thalassemic patients by the fact that
their normoblasts carried intercellular adhesion molecule-2
(ICAM-2) and platelet endothelial cell adhesion molecule-1
(PECAM-1).
Moreover, the role of red cell size in the pathogenesis of
hypercoagulability has been studied by Atichartakarn and
his colleagues.28 They reported that smaller sized RBCs are
more thrombogenic especially after splenectomy. Their data
suggested that the efﬁcient clearing of these abnormal RBCs
by the spleen protects against the hypercoagulable condition.
In the present study a signiﬁcant increase in the platelet
count was observed among splenectomized patients. This is
due to the fact that the spleen is the main organ for plateletsequestration.10 Moreover, post-splenectomy thrombocytosis,
by itself predisposes these patients to thrombosis. Ataga et
al.16 added that splenectomized thalassemic patients had a
shortened platelet life span compared to healthy individuals
splenectomized for trauma. Eldor and Rachmilewitz suggested
that the shortened life span was caused by enhanced platelet
consumption, a feature usually associated with active throm-
botic disease and hypercoagulabe states.29
Furthermore, a signiﬁcant positive correlation was found
between plasma sP-selectin and serum ferritin as well as total
leucocytic count reﬂecting the interplay between platelet acti-
vation, iron free radicals and inﬂammation. Our ﬁndings are
supported by Warefeld and Myers30 who reported that throm-
bosis and inﬂammation are inter-related.
Regarding substance P, to our knowledge it has not been
studied in patients with thalassemia. In the present study, sig-
niﬁcantly elevated levels of substance P were observed in pa-
tients with thalassemia compared to the control and the
elevated levels were more prominent in splenectomized pa-
tients reﬂecting a higher level of platelet activation.
In the present study, we found a signiﬁcant positive corre-
lation between substance P and sP-selectin, reﬂecting the role
of substance P in inducing inﬂammation and platelet activa-
tion. In agreement to our ﬁndings, Jone et al.31 deﬁned the role
for substance P in the activation of platelet function and
thrombus formation. They showed that substance P can stim-
ulate platelet activation and aggregation, and that platelets
contain substance P immunoreactivity that is released upon
activation. In addition, inhibition or deﬁciency of the neurok-
inin receptor 1 (NK1) of this neuropeptide resulted in substan-
tially reduced thrombus formation in vitro. Moreover,
Graham et al.32 stated that NK1 receptor blocking antibodies
inhibit platelet responses to collagen, indicating that NK1 ago-
nists are released from activated platelets and act as paracrine
agonists.
To the best of our knowledge, this is the ﬁrst report on
tachykinin neuropeptide, substance P in patients with thalasse-
mia. The observed high levels add a new mechanism to the al-
ready well established causes of platelet activation and
hypercoagulability in thalassemic patients.
Plasma substance P and soluble P-selectin as biomarkers of b-thalassemia induced hypercoagulability 1115. Conclusion
 Substance P and sP-selectin might have a role in platelet
activation and subsequent hypercoagulability in thalasse-
mic patients.
 If proved by large scale studies, P-selectin and substance P
could be novel targets in preventing the complications of
thalassemia.
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